Compare CBNK & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | CADL |
|---|---|---|
| Founded | 1974 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 641.2M |
| IPO Year | 2018 | 2021 |
| Metric | CBNK | CADL |
|---|---|---|
| Price | $42.10 | $9.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $44.08 | $22.11 |
| AVG Volume (30 Days) | 136.9K | ★ 1.1M |
| Earning Date | 10-26-2026 | 11-24-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 60.85 | 58.62 |
| EPS | ★ 2.40 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $10.68 | N/A |
| P/E Ratio | $17.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.40 | $4.35 |
| 52 Week High | $44.76 | $14.00 |
| Indicator | CBNK | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 50.88 |
| Support Level | $35.70 | $7.70 |
| Resistance Level | N/A | $9.42 |
| Average True Range (ATR) | 0.94 | 0.65 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 40.77 | 68.69 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.